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Abstract
The nine serotypes of avian paramyxoviruses (APMVs) are frequently isolated from domestic and wild birds worldwide.
APMV-1, also called Newcastle disease virus, was shown to be attenuated in non-avian species and is being developed as a
potential vector for human vaccines. In the present study, we extended this evaluation to the other eight serotypes by
evaluating infection in BALB/c mice. Mice were inoculated intranasally with a prototype strain of each of the nine serotypes
and monitored for clinical disease, gross pathology, histopathology, virus replication and viral antigen distribution, and
seroconversion. On the basis of multiple criteria, each of the APMV serotypes except serotype 5 was found to replicate in
mice. Five of the serotypes produced clinical disease and significant weight loss in the following order of severity: 1, 2.6,
9.7. However, disease was short-lived. The other serotypes produced no evident clinical disease. Replication of all of the
APMVs except APMV-5 in the nasal turbinates and lungs was confirmed by the recovery of infectious virus and by
substantial expression of viral antigen in the epithelial lining detected by immunohistochemistry. Trace levels of infectious
APMV-4 and -9 were detected in the brain of some animals; otherwise, no virus was detected in the brain, small intestine,
kidney, or spleen. Histologically, infection with the APMVs resulted in lung lesions consistent with broncho-interstitial
pneumonia of varying severity that were completely resolved at 14 days post infection. All of the mice infected with the
APMVs except APMV-5 produced serotype-specific HI serum antibodies, confirming a lack of replication of APMV-5. Taken
together, these results demonstrate that all APMV serotypes except APMV-5 are capable of replicating in mice with minimal
disease and pathology.
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Introduction
The family Paramyxoviridae i sl a r g ea n dd i v e r s ea n di n c l u d e sv i r u s e s
that have been isolated from a wide variety of mammalian and avian
species around the world [1]. Some members of the family are
responsible for major human and animal diseases, while others cause
inapparent infections. The viruses belonging to this family are
pleomorphic and enveloped and contain a non-segmented, negative-
sense, single-stranded RNA genome of 13–19 kb. On the basis of virus
structure, genome organization and sequence relatedness, the family
Paramyxoviridae is divided in to two subfamilies: Paramyxovirinae and
Pneumovirinae [1]. The subfamily Paramyxovirinae is divided into five
genera: Respirovirus (including Sendai virus and human parainfluenza
virus types 1 and 3), Rubulavirus (including simian virus type 5, mumps
virus, and human parainfluenza virus types 2 and 4), Morbillivirus
(including measles and canine distemper viruses), Henipavirus (compris-
ing Hendra and Nipah viruses), and Avulavirus (comprising the avian
paramyxoviruses [APMVs]). Subfamily Pneumovirinae contains two
genera, Pneumovirus (including human respiratory syncytial virus and
bovine respiratory syncytial virus) and Metapneumovirus (comprising
human metapneumovirus and the avian metapneumoviruses) [1,2].
All the paramyxoviruses isolated from avian species are
classified into genus Avulavirus, representing the APMVs, and
genus Metapneumovirus, representing the avian metapneumoviruses.
The APMVs have been divided into nine serotypes (APMV 1 to 9)
based on hemagglutination inhibition (HI) and neuraminidase
inhibition (NI) assays [3]. Recently, APMVs were isolated from
Rockhopper Penguins in the Falkland Islands. Serological and
genome characterizations suggested that these viruses probably
represent a new serotype (APMV-10) [4]. APMV-1, which
includes all strains of NDV, has been extensively characterized
because virulent NDV strains are important causes of disease in
chickens. Complete genome sequences have been determined for a
number of NDV strains, and there is extensive information on
NDV molecular biology and pathogenesis [5–15]. Comparatively
little is known about the other eight APMV serotypes. As an initial
step towards their characterization, complete genome sequences of
APMV serotypes 2 to 9 were recently determined [16–26].
APMV-1 (NDV) strains are divided into three pathotypes:
highly virulent (velogenic) strains that cause severe respiratory and
neurologic diseases in chickens; moderately virulent (mesogenic)
strains that cause milder disease, and nonpathogenic (lentogenic)
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known about the biological characteristics and pathogenicity of
APMV-2 to -9. APMV-2 has been associated with severe
respiratory disease and drop in egg production in turkeys
[27,28]. APMV-3 has been associated with encephalitis and high
mortality in caged birds, respiratory diseases in turkeys and
stunted growth in young chickens [29,30]. APMV-5 causes disease
in budgerigars that is characterized by depression, dyspnoea,
diarrhea and high mortality [31]. APMV-6 and -7 cause mild
respiratory disease in turkeys and are associated with a drop in egg
production [32–34]. APMV-4, -8, and -9, isolated from ducks,
waterfowl, and other wild birds did not produce any clinical signs
of viral infection in chickens [35–39]. Recently, we performed
experimental infection of 1-day-old chicks and 4-week-old
chickens and turkeys with APMV-2 strains, Yucaipa and Bangor,
and documented viral infection in the gastrointestinal and
respiratory tracts [40]. We also performed experimental infection
of 2-week-old chickens and turkeys with APMV-3 strains,
Netherlands and Wisconsin, and documented viral infection in
the brain, lungs, spleens, trachea, pancreas and kidney [41].
In the last 10 years, reverse genetic techniques have made it
possible to engineer NDV as a potential vaccine vector for delivery
of a number of foreign antigens not only in avian hosts but also in
murine and nonhuman primate models [42–50]. In addition,
NDV has been evaluated as a promising broad spectrum oncolytic
agent in a mouse model [51–54]. Safety of different strains of
NDV, due to attenuation by host range restriction, has been
documented in these animal models [55]. In the future, we plan to
use reverse genetic techniques to evaluate other APMV serotypes
(serotype 2 to 9) as vaccine vectors and oncolytic agents. However,
small laboratory animal models will be needed to evaluate their
replication, immunogenicity and safety. In the current study, we
sought to evaluate mice as a small animal model for infection with
APMV 2 to 9. We inoculated BALB/c mice intranasally with
APMV serotypes 1 to 9 and monitored clinical signs and viral
replication and tropism in a number of possible target organs. We
further studied the serological responses to APMV infection in
these animals. The results showed that BALB/c mice are
susceptible to infection with all of the APMV serotypes except
serotype 5. Viral replication occurred mostly in the upper and
lower respiratory tracts. The data generated using this animal
model will be helpful in elucidating mechanisms of immunity and
pathogenesis and evaluating candidate recombinant vaccines.
Materials and Methods
Cells and viruses
Chicken embryo fibroblast (DF1) and African green monkey
kidney (Vero) cell lines, obtained from the American Type Culture
Collection (ATCC, Manassas, VA), were grown in Dulbecco’s
modified Eagle medium (DMEM) containing 10% fetal bovine
serum (FBS) and maintained in DMEM with 5% FBS. The
prototype strains of all nine APMV serotypes used in this study
were: APMV-1 strain LaSota/46, APMV-2 strain chicken/
Yucaipa/California/56, APMV-3 strain parakeet/Netherland/
449/75, APMV-4 strain duck/Hongkong/D3/75, APMV-5 strain
budgerigar/Kunitachi/74, APMV-6 strain duck/HongKong/18/
199/77, APMV-7 strain dove/Tennessee/4/75, APMV-8 strain
goose/Delaware/1053/76, and APMV-9 strain duck/New York/
22/78. All of the strains except for serotype 5 were obtained from
National Veterinary Services Laboratory, Ames, Iowa. APMV-5
strain budgerigar/Kunitachi/74 was kindly provided by Dr. Ian
Brown, the Veterinary Laboratories Agency, Weybridge, Surrey,
UK. All of the APMV serotypes except serotype 5 were grown in
the allantoic cavity of 9-day-old specific-pathogen-free (SPF)
embryonated chicken eggs. APMV serotype 5 was grown in Vero
cells. The allantoic fluids from infected eggs were collected 96 h
post-inoculation and virus titers were determined by hemaggluti-
nation (HA) assay with 0.5% chicken RBC. In the case of APMV-
5, the titer was determined by plaque assay on Vero cells. The
APMV-5 samples were inoculated in triplicate onto 24-well plates
of Vero cells at 80% confluency, incubated for 1 h, washed with
PBS, overlaid with 0.8% methylcellulose, and observed for plaque
production until 7 days post inoculation (dpi). The cells were fixed
with methanol and stained with 1% crystal violet. Values for each
tissue sample were based on average plaque count from three
wells.
Preparation of hyperimmune antiserum against the viral
nucleocapsid (N) protein of each serotype of APMV
Each APMV serotype strain described above was purified on a
sucrose gradient and the virion proteins were separated on a 10%
SDS-polyacrylamide gel and negatively stained using E-Zinc TM
reversible stain kit (Pierce, Rockford, IL). The N protein specific
band was excised from the gel and destained with Tris-glycine
buffer pH 8. The excised gel band was minced in a clean pestle
and mixed with elution buffer (50 mM Tris-HCl buffer pH 8,
150 mM NaCl, 0.5 mM EDTA, 5 mM DTT and 0.1% SDS) and
transferred to the upper chamber of a Nanosep centrifugal device
(Pall Life Sciences, Ann Arbor, MI, USA). After centrifugation two
times, the eluted protein in the supernatant was quantified and
0.2 mg of protein was mixed with complete Freund’s adjuvant and
injected subcutaneously into a rabbit. After two weeks, a booster
immunization was given with 0.2 mg of protein mixed with
incomplete Freund’s adjuvant and 2 weeks later the hyperimmune
sera were collected. The sera were tested by Western blot and were
found to recognize specifically the N protein of the respective
APMV serotypes (data not shown).
Experimental infection of Mice
BALB/c mice aged 4 weeks, of either gender, were obtained
from Charles River Laboratories, Wilmington, Massachusetts.
Mice were housed in microisolator cages in our Bio Safety Level-2
facility and provided water and food ad libitum. Mice were
housed in groups of 6 for inoculation of each APMV serotype.
Mice were anaesthetized by isofluorane and inoculated intrana-
sally with 50 ml of freshly harvested allantoic fluid containing 2
7
HA units of each APMV serotype, except for serotype 5 which
contained 3610
3 PFU/ml of cell culture harvested virus. A group
of 6 mice was mock infected with normal allantoic fluid. Mice
were weighed and examined two times daily for clinical signs,
change in activity and behavior. Three mice from each group
were euthanized at 3 day post inoculation (dpi) and other three at
14 dpi by CO2 asphyxiation. Necropsies were performed
immediately and tissues from lung, nasal turbinate, brain, small
intestine, kidney and spleen were collected. One half of each tissue
sample was immediately processed for virus detection and
quantification and the other half was stored in 10% neutral
buffered formalin for histopathology and immunohistochemistry
experiments. On 14 dpi, blood was collected from each mouse
just before euthanasia and sera were prepared for analysis. All the
animal research was conducted according to the guidelines
approved by Institutional Animal Care and Use Committee of the
University of Maryland. The protocol number is R-09-47
[Immunogenicity and protection efficacy of recombinant NDV
expressing foreign antigens in mammalian models (mice and
ferrets)].
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Tissues collected from different organs were homogenized in
1 ml of ice-cold DMEM. Tissue homogenates were centrifuged at
4uC for 10 min at 10006g and supernatants were collected. For
virus detection, 100 ml of clarified homogenate from each tissue
was injected into allantoic cavities of five 9-day-old embryonated
SPF chicken eggs. Eggs were incubated at 37uC for 4 days.
Allantoic fluid was collected from each egg and the presence of
virus was detected by hemagglutination (HA) test. For quantifica-
tion of virus, clarified homogenate from each tissue was diluted in
serial 10-fold dilutions in DMEM. The dilutions were inoculated
in triplicate onto DF1 cell monolayers in 96-well plates and
incubated at 37uC for 1 h. The wells were overlaid with 0.8%
methylcellulose in DMEM supplemented with 10% normal
allantoic fluid and 2% FBS and incubated at 37uCi naC O 2
incubator for 4 days. The monolayers were washed with PBS,
permeabilized with 100% cold methanol, and incubated with a
1:300 dilution of primary N-specific antibody in PBS produced as
described above. After three washes with PBS, plates were
incubated with a 1:1000 dilution of secondary antibody (Alexa
Fluor 488 conjugated goat anti rabbit immunoglobulin G
antibodies). After a further wash cycle, plates were viewed under
a fluorescent microscope and fluorescent foci were counted.
Histopathology and Immunohistochemistry
Tissues from infected and control mice were examined by
histopathology and immunohistochemistry. Paraffin embedded
sections of all the tissues were prepared at Histoserve, Inc.
(Maryland, USA). The 5 micron tissue sections were stained with
hematoxylin and eosin for histopathology. The severity of
inflammation in lungs and nasal turbinate of each APMV infected
mouse was assessed based on the extent of fibrin, edema, and
mixed inflammatory cells (neutrophils, macrophages, lymphocytes,
plasma cells), necrotic cellular debris, and hemorrhage in alveolar
spaces and septae.
Immunohistochemical staining was performed on lung and
nasal turbinate tissues to detect viral N protein using the following
protocol. Briefly, tissue sections were deparaffinized in 2 changes
of xylene (5 mins each) and hydrated by incubation in 2 changes
each of 100% (3 mins each), 95% (1 min each), and 80% (1 min
each) ethanol followed by washing in distilled water. Slides were
heated for 40 mins in a staining dish containing sodium citrate
buffer (10 mM citric acid, 0.05% Tween 20, pH 6.0) until the
temperature reached 95–100uC, followed by cooling to room
temperature. Sections were washed two times in PBS-Tween 20
for 2 min each, blocked with 2% normal goat serum in PBS for
30 mins, and incubated with 1:200 dilution of primary antibody
(hyperimmune sera raised against N protein of a particular APMV
serotype) in PBS for 1 h at room temperature. The sections were
washed three times with PBS-Tween 20 for 2 min each and
incubated with 1:1000 dilution of secondary antibody (Alexa Fluor
488 conjugated goat anti rabbit immunoglobulin G antibodies) in
PBS for 1 h. After a further wash cycle, the sections were mounted
with glycerol and viewed under fluorescent microscope.
Serological analysis
The antibody levels in serum samples collected from mice
infected with APMVs on 14 dpi, were evaluated by hemaggluti-
nation inhibition (HI) assay except in the case of APMV-5 [56]. In
our standard HI assay, the normal mice sera produced nonspecific
HI. Therefore a modified HI assay was used. Briefly, 25 ml of mice
serum was first treated with 50 ml of receptor destroying enzyme II
(catalog number YCC 340–122; Accurate Chemical and Scien-
tific, Westbury NY) at a 1:3 ratio (vol/vol) at 37uC overnight.
Then 25 ml of 5% sodium citrate was added and incubation was
continued at 56uC for 30 min. Each serum sample was allowed to
cool to room temperature and 100 ml of packed chicken RBCs
were added. After incubation at 4uC for 30 min, samples were
centrifuged at 10006g for 10 min. Supernatants were used for HI
assay. For the HI assay, twofold serial dilutions of treated sera
(50 ml) were prepared, and each dilution was combined with 4 HA
units of a particular APMV serotype. Following 1 h of incubation,
50 ml of 1% chicken RBC was added and incubated for 30 min at
room temperature, and hemagglutination was scored. In the case
of APMV-5, antibody titers were measured by a plaque reduction
assay. Briefly, the sera were heat inactivated at 56uC for 30 mins.
Ten-fold dilutions of sera were made and mixed with a constant
amount of APMV-5 (3610
3 PFU), and incubated at room
temperature for 1 h in a shaker. The antigen antibody mixtures
were analyzed by plaque assay as described above. The serum titer
that reduced plaque numbers by 70% was the end point titer.
Results
Clinical disease and gross pathology
Four-week-old BALB/c mice in groups of six were inoculated
by the intranasal route with 2
7 HA units of APMV serotypes 1 to 9
except in the case of serotype 5, for which 3610
3 PFU/ml of virus
were inoculated. Three animals from each group were sacrificed
3 dpi, and the remaining three were sacrificed 14 dpi. None of the
mice infected with APMV serotypes 3, 4, 5 and 8 displayed any
overt clinical signs and loss of weight (Fig. 1). At 1 dpi, the mice
infected with APMV serotype 1 and 2 had a pronounced decrease
in their physical activity, a tendency to huddle and very ruffled fur
compared to control mice. The mice infected with APMV
serotypes 6, 7 and 9 also presented these clinical signs, which
were less marked than those of the mice infected with serotypes 1
and 2. Mice infected with serotypes 1 and 2 exhibited more weight
loss than mice infected with serotypes 6, 7 and 9. The loss in
weight was observed until day 4 in mice infected with serotypes 1
and 2, until day 3 in mice infected with serotypes 6 and 9, and
until day 2 in mice infected with serotype 7. Further, the weight
gain remained poor in mice infected with serotypes 1 and 2 after
4 dpi. None of the mice infected with serotypes 1 to 9 died of
disease. When the animals were sacrificed 3 dpi and 14 dpi, the
following tissues were collected: lung, nasal turbinate, brain,
spleen, kidney and small intestine. In all cases, gross examination
revealed normal tissue morphology with no noticeable gross
lesions.
Virus isolation and titration in tissue samples
To determine the sites of APMV replication, one half of each
sample of lung, nasal turbinate, brain, spleen, kidney and small
intestine tissue collected 3 dpi and 14 dpi was homogenized and
clarified supernatants were prepared. For each of the serotypes
except APMV-5 (which does not grow in the allantoic cavity of
eggs), aliquots were inoculated into the allantoic cavity of
embryonated 9-day-old chicken eggs, and 4 dpi the allantoic fluid
was collected and assayed for virus infection by HA test (Table 1).
For all of the serotypes of APMV except serotype 5, virus was
detected from the lungs and nasal turbinates at 3 dpi. APMV
serotypes 4 and 9 also were detected in the brain in two mice each
at 3 dpi. Virus was not detected in any other tissues isolated 3 dpi,
or in any tissue isolated 14 dpi.
For quantification of the replication of each APMV, homoge-
nates of tissue samples that were positive for virus isolation in eggs
were used to generate 10-fold dilution series that were inoculated
onto chicken DF1 cells and incubated under methylcellulose
Experimental Infection of Mice with APMV 1 to 9
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were analyzed in parallel. Immunofluorescence staining for the N
protein 4 dpi revealed foci with strong positive intracellular
staining in the case of samples from the lungs and nasal turbinates
for each of the APMV serotypes except APMV-5, for which no
virus was detected (Fig. 2). The mean virus titers from lungs of the
mice infected with APMV serotypes 1, 2, 3, 4, 6, 7, 8 and 9 were
2610
2,3 610
2,7 610
1,2 610
2,2 610
2,3 610
1,5 610
2 and 9610
2,
respectively (Table 2). The mean virus titers from nasal turbinates
of the mice infected with APMV serotypes 1, 2, 3, 4, 6, 7, 8 and 9
were 3610
1,6 6,2 610
1,1 610
2,3 610
2,1 610
1,2 610
2 and
8610
2, respectively. These results indicated the titer of APMV
serotype 9 was higher than other serotypes in the lung and nasal
turbinates, suggesting that it was the most permissive APMV for
replication in mice. The brain tissue samples of APMV serotypes
4 and 9 infected mice that were positive for infection of
Figure 1. Weight loss in mice infected with APMV serotypes 1 to 9. Mice in groups of 6 were inoculated with allantoic fluid containing 2
7 HA
units of each APMV serotype except serotype 5, which contained 3610
3 PFU/ml of cell culture harvested virus. The control group was inoculated
with normal allantoic fluid. The mice were weighed daily and weight lost was calculated as a percent of the weight on day 0. Data depict the mean 6
SD from 3 mice per group.
doi:10.1371/journal.pone.0016776.g001
Table 1. Virus isolation from the indicated tissue harvested from mice 3 dpi with APMV serotypes 1 to 9*.
APMV Serotype Lung Nasal turbinate Spleen Kidney Small intestine Brain
1 +++ +++ ----
2 +++ +++ ----
3 +++ +++ ----
4 +++ +++ ---++
5 ND ND ND ND ND ND
6 +++ +++ ----
7 +++ +++ ----
8 +++ +++ ----
9 +++ +++ ---++
*Mice in groups of 3 were inoculated with 50 ı `l of allantoic fluid containing 2
7 HA units of each APMV serotype except serotype 5, which contained 3610
3 PFU/ml of cell
culture harvested virus. The control group was inoculated with normal allantoic fluid. Tissues were harvested 3 dpi and homogenized, and clarified supernatant fluid
was inoculated into 9-day-old embryonated eggs and tested for virus 4 days later by HA assay.
+ =each + indicates isolation of virus from one mice.
- =no virus was isolated.
ND=not detected.
doi:10.1371/journal.pone.0016776.t001
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detected in any sample from day 14, indicating viral clearance.
The APMV-5 samples also were inoculated onto African green
monkey Vero cells, where no virus could be detected from any of
the tissue harvested from mice 3 dpi or 14 dpi by immunofluo-
rescence staining. This indicated that APMV-5, alone among the
APMV serotypes, was not recoverable from infected mice.
Immunonohistochemistry
The remaining half of each of the tissue samples isolated on
3 dpi and 14 dpi from the mice infected with the APMV serotypes
was fixed and embedded in paraffin, and tissue sections were
prepared. The tissue sections representing all of the collected tissue
samples from the virus-infected and mock-infected animals from
3 dpi and 14 dpi were deparaffinized and immunostained using
polyclonal antiserum specific to the N protein of the corresponding
APMV serotype. Large amounts of APMV-specific N antigen was
detected at 3 dpi by immunofluorescence staining of lungs and
nasal turbinate tissue samples of mice infected with all the
serotypes of APMV except serotype 5, which was negative (Fig. 3a
and 3b). In the lungs of mice infected with each of the APMV
serotypes except serotype 5, the viral antigen was localized mainly
on the respiratory epithelium lining small and medium bronchi. In
nasal turbinates of mice infected with each of the APMV serotypes
except serotype 5, the virus specific immunoflourescence was
observed on nasal epithelium lining the turbinate bone. No viral N
antigen was detected in tissue samples from brain, spleen, kidney
and small intestine of mice 3 dpi or 14 dpi with any the APMV
serotypes, or from the lungs and nasal turbinates 14 dpi.
Histopathology
Tissue sections also were stained with hematoxylin and eosin and
examined for histopathology. Lesions were observed in the lungs at
3 dpi in all the mice infected with each of the APMV serotypes
except serotype 5, for which no histopathology was evident. Lesions
Figure 2. Immunofluorescence visualization of foci formed in DF-1 cells infected with each of the 9 APMV serotypes. Mice were
infected with each of the APMV serotypes and lungs were harvested 3 dpi and homogenized, and the clarified supernatants were inoculated onto
DF-1 cells that were incubated 4 days under methycellulose prior to immunostaining with polyclonal antiserum specific to the N protein of the
respective serotype. Viruses: APMV-1 (panel B), APMV-2 (panel C), APMV-3 (panel D), APMV-4 (panel E), APMV-5 (panel F), APMV-6 (panel G), APMV-7
(panel H), APMV-8 (panel I), APMV-9 (panel J), and mock-infected (panel A).
doi:10.1371/journal.pone.0016776.g002
Table 2. Virus titers in the indicated tissue harvested from
mice 3 dpi with APMV serotypes 1 to 9, expressed as mean
fluorescent foci/gram of tissue.
APMV serotype Lung Nasal Turbinate Brain
1 2610
2 3610
1 -
2 3610
2 6610
1 -
3 7610
1 2610
1 -
4 2610
2 1610
2 -
5 -- -
6 2610
2 3610
2 -
7 3610
1 1610
1 -
8 5610
2 2610
2 -
9 9610
2 8610
2 -
All the values are the mean of 3 mice per group.
*Titers were determined by serial dilution of clarified tissue homogenates from
the experiment in Table 1 onto DF1 cells, which were overlaid with
methylcellulose and immunostained 4 days later with N protein-specific
antisera to detect viral foci.
- =no virus was isolated.
doi:10.1371/journal.pone.0016776.t002
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severe in the airways. Severe multifocal to coalescing acute
necrotizing bronchointerstitial pneumonia was noticed in lung
tissues infected with APMV-1 and APMV-2, while mild to subacute
bronchointerstitial pneumonia was observed in the other APMVs
infected mice (Fig. 4). There was involvement of bronchiolar
Figure 3. Immunohistochemistry of sections of lungs (3a) and nasal turbinates (3b) harvested from mice 3 dpi with each of the 9
APMV serotypes. Mice were mock-infected (panel A) or infected with APMV-1 (panel B), APMV-2 (panel C), APMV-3 (panel D), APMV-4 (panel E),
APMV-5 (panel F), APMV-6 (panel G), APMV-7 (panel H), APMV-8 (panel I), and APMV-9 (panel J). Immunofluoresence was performed with polyclonal
antiserum specific to the respective serotype N protein (magnification, 6400). In sections of the lungs from mice infected with different APMVs,
immunofluorescence was evident around the bronchial epithelium (Fig. 3a). In sections of the nasal turbinates from mice infected with different
APMVs, immunofluorescence was evident around the bronchial epithelium, at the apical surface of the ciliated epithelial cells and in the cytoplasm
(Fig. 3b). Bronchioles are shown by arrow.
doi:10.1371/journal.pone.0016776.g003
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samples,alveolarhemorrhage and fibrin, which maybe necrotizing,
was observed. In addition, syncytia involving type II pneumocytes
was evident for each of the APMVs except for APMV-4, APMV-5,
and APMV-8 (Fig. 4 marked arrow). Microscopic lesions were not
found in the lungs of any mouse at 14 dpi. In addition, lesions were
not found in any other tissues on either day.
Seroconversion
The sera of the mice infected with the different serotypes of
APMV were collected at 14 dpi. Sera from mice infected with each
of the APMV serotypes except serotype 5 were analyzed for virus-
specific antibodies by a modified HI assay using chicken erythro-
cytes. The HI titers of the pre-infection and control mice were 2 or
less. An HI titer of greater than 8 was considered positive. Every
infected mouse seroconverted, indicating that viral replication had
occurred (Table 3). The mean serum HI titers of mice infected with
APMV serotypes 1, 2, 3, 4, 6, 7, 8 and 9 were 1:64, 1:64, 1:64, 1:16,
1:16, 1:64, 1:64, 1:64, respectively. In the case of APMV-5, which
does not hemagglutinate, antibody titers were measured by a plaque
reduction assay. However, none of the mice infected with APMV-5
developed detectable neutralizing serum antibodies.
Discussion
APMVs are frequently isolated from wide variety of avian
species around the world and have been grouped into nine
serotypes based on antigenic relatedness involving the HN protein.
Among the nine serotypes, APMV-1 (NDV) is the most studied
member due to its importance as a major pathogen of poultry.
Figure 4. Histopathology in sections of lungs harvested from mice 3 dpi with each of the APMV serotypes. Mice were mock-infected (panel
A) or infectedwith APMV-1 (panelB), APMV-2 (panelC),APMV-3 (panelD),APMV-4(panelE), APMV-5 (panelF),APMV-6 (panelG),APMV-7(panelH),APMV-
8(panelI),andAPMV-99panelJ).Sectionswerestainedwithhematoxylinandeosin(magnification,6400). Inmock-infected mice, the bronchiole is lined by
a single layer of epithelial cells, alveoli are filled with air (although partially collapsed) and lined by flattened type I pneumocytes and there is mild acute
alveolar hemorrhage likely secondary to CO2 euthanasia. APMV-5 infected mice had no detectable lesions and were indistinguishable from mock-infected
mice. In APMV-1 and -2 infected mice, severe subacute diffuse necrotizing bronchointerstitial pneumonia was observed (panels B and C). Further, alveolar
spaces and septae arefilled with hemorrhage, fibrin, edema, and mixed inflammatory cells (neutrophils,macrophages, lymphocytes, plasma cells), as well as
necrotic cellular debris (panels B and C). In APMV-1 infected mice, alveolar spaces/interstitium are more severely affected than are the airways (panel B).
Further, bronchiolar epithelial cells are hypertrophied with karyomegally and occasional individual cell necrosis/apoptosis was also observed (panel B). In
APMV-7 and -9 infected mice, there is type II pneumocyte hypertrophy as well as endothelial cell hypertrophy (black arrows in panels H and J). In APMV-8
infected mice, there are neutrophils in expanded alveolar septae (black arrow in panel I). However, mild bronchointerstitial pneumonia was observedi n
mice infected with some APMVs with different degrees of bronchiole damage (panels D, E and G to J).
doi:10.1371/journal.pone.0016776.g004
Table 3. Serum antibody responses against APMV serotypes
1–9 in infected mice
a.
APMV serotype HI antibody titer
b
1 1:64
2 1:64
3 1:64
4 1:16
5 -
6 1:16
7 1:64
8 1:64
9 1:64
All the values are averages from three independent experiments.
aMice in groups of 3 were inoculated as in Table 1. Serum samples were
collected before inoculation and 14 dpi.
bThe hemagglutination inhibition (HI) titer is expressed as the reciprocal of the
highest serum dilution causing complete inhibition of four HA units of NDV.
- =not detected.
doi:10.1371/journal.pone.0016776.t003
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and wild birds, but have been largely uncharacterized until
recently. APMV-1 has been shown to infect not only avian species
but also non-avian species, although its replication is restricted in
non-avian hosts. APMV-1 is being developed as promising viral
vaccine vector for delivery of a number of foreign antigens of
animal and human pathogens. Further, APMV-1 has been
developed as safe and effective oncolytic agent both in mouse
models and also in human clinical trials [51–53,57–59]. Therefore,
it is of interest to also evaluate APMV serotypes 2 to 9 as potential
vaccine vectors and oncolytic agents. However, the ability of
APMV serotypes 2 to 9 to replicate in mammalian hosts was
unknown.
The goal of this study was to evaluate intranasal infection by
representative APMVs in mice to assess pathogenesis in a non-
avian host and to identify a small laboratory animal model for
further studies. Mice were evaluated for permissiveness to infection
by APMV serotypes 1 to 9, clinical disease, magnitude and
location of replication in the respiratory tract, dissemination to
other tissues, disease, histopathology, and induction of antibodies.
Inbred mice have been commonly used to study replication and
pathogenesis of various viruses, to screen attenuation phenotypes
of live virus vaccines, and to evaluate immune responses and
protective efficacy elicited by virus vaccine candidates. This
animal model is desirable for a number of reasons (i) Inbred mice
represent a genetically homogenous model for which many
reagents are available (ii) The degree of replication in the
respiratory tract and other organs is readily measured (iii)
Pathogenesis is readily monitored (iv) Innate, cellular, humoral
and mucosal immune responses can be readily measured and (v)
The mouse has the same body temperature as humans, and is a
convenient mammalian host.
In this study, we have evaluated the replication and pathoge-
nicity of APMV serotypes 2 to 9 in mice by a natural (intranasal)
route of infection. Mice infected with different serotypes of APMV
showed relatively mild or no clinical signs. Mice infected with
APMV serotypes 1, 2, 6, 7 and 9 exhibited loss of weight that was
more marked with serotypes 1 and 2. However, these mice
recovered fully by 7
th day of infection and showed no further
clinical signs. The order of severity of clinical disease and weight
loss was: 1, 2.6, 9.7. The other serotypes did not induce clinical
disease. Mice infected with any of the APMV serotypes exhibited
no gross pathological lesions in any of the organs.
Each of the APMV serotypes replicated to low-to-moderate
titers in the lungs and nasal turbinates on 3 dpi except for serotype
5, for which infectious virus could not be recovered from any tissue
at any time point. In the case of APMV serotypes 4 and 9, the
brain tissue samples from two of the three infected mice in each
group were positive for infectious virus 3 dpi when assayed in
embryonated eggs, but were negative for virus recovery in cell
culture. This suggests that the viral titers in the brain samples were
very low. Infectious virus was not detected in any other tissue
samples for any serotype. These findings indicate that replication
by the APMV serotypes is largely restricted to the upper and lower
respiratory tracts. In our study virus could not be detected in
spleen in contrast to previous findings [60]. These discrepancies
could be due to the differences in route of inoculation in two
studies. Consistent with this, mild histopathological lesions were
observed 3 dpi in the respiratory tract for all of the serotypes
except APMV-5, which was negative. Lesions were not observed
in any other tissues. Also, immunohistochemical staining detected
viral N antigen in the lungs and nasal turbinates 3 dpi, but not in
any other tissue. An interesting finding was the presence of large
amounts of viral antigens at the epithelial cell linings, suggesting
that these viruses have tropism towards the superficial layer of
epithelial cells. On 14 dpi, virus was not detected in any of the
tissues for any of the APMV serotypes, either by virus isolation or
immunostaining. In addition, no histopathologic lesions remained.
Thus, the infections had completely resolved by 14 dpi.
The different APMV serotypes induced a spectrum of disease
severity. At one extreme, mice infected with serotypes 1 and 2
exhibited ruffled fur, huddling, decreased physical activity, and
substantial weight loss. At the other extreme, serotypes 3, 4, 5, and
8 did not exhibit any disease signs apart from marginal weight loss
in some instances. Serotypes 6, 7, and 9 were intermediate in
disease signs. The clinical disease that was observed was short-
lived. Increased disease was not reflected by substantial increases
in the titer of infectious virus recovered from the lungs and nasal
turbinates. For example, APMV-1 and -2 induced the most
clinical disease, but the viral titers observed with APMV-1 and -2
were similar to those with APMV-4, -6, -8, and -9 for which
disease was either less (APMV-6 and -9) or not apparent (APMV-4
and -8). Similarly, the amount of antigen observed in the epithelial
linings of the lungs and nasal turbinates was extensive for all of the
viruses except APMV-5, and thus usually was not accompanied by
severe disease. These findings are favorable with regard to the
possible use of these viruses as vaccine vectors, since extensive
antigen expression with minimal disease and minimal-to-moderate
virus replication are desired characteristics. Serological analysis
demonstrated a humoral response in the mice inoculated with
different serotypes of APMVs except serotype 5, a further
indication that APMV-5 did not replicate significantly. These
results show that, with the exception of serotype 5, the APMVs are
capable of infecting mice by the intranasal route with extensive
antigen expression and minimal disease.
Previously, pathogenicity of APMV-3 strain Netherlands in 9-
day-old embryonated chicken eggs, 1-day and 2-week-old chickens
and turkeys was examined [41]. The mean death time (MDT) in
9-day-old embryonated chicken eggs was 112 h and intracerebral
pathogeneicity index (ICPI) in 1-day-old chicks was 0.39. It caused
mild respiratory disease in 1-day-old chickens and turkeys after
inoculation through oculonasal route. In 2-week-old chicken and
turkeys, it did not cause any disease. All the birds were
seroconverted and the virus was detected in brain, lungs,
alimentary tract, spleen, trachea, pancreas and kidney. Subbiah
et al. [40] studied pathogenicity of APMV-2 strain Yucaipa in 9-
day-old embryonated chicken eggs, 1-day and 4-week-old chickens
and turkeys. The MDT in 9-day-old embryonated chicken eggs
was more than 168 h and ICPI in 1-day-old chicks was zero. After
oculonasal inoculation, it did not cause any disease in 4-week-old
chickens and turkeys, although all the birds were seroconverted.
The virus was detected in respiratory and alimentary tracts. In
another study, experimental infection of 1-day-old chicks with
APMV serotypes 2, 4 and 6 resulted in viral infection and virus
was recovered from infected birds’ trachea, lungs, gut, and
pancreas [61]. Similar to the findings in chickens, we were able to
detect the virus in respiratory tract of mice but we were not able to
isolate infectious virus or detect viral antigen for any of the APMV
serotypes in the spleen, kidney and small intestines of the mice,
suggesting that the tropism of these APMVs is more restricted in
mice, presumably reflecting reduced replication and host-range
restriction in this non-avian species. However, the observation that
trace amounts of APMV-4 and -9 were detected in the brain will
need to be further evaluated.
Our results identified BALB/c mice as a small animal model
that supported replication in the respiratory tract of all of the
APMVs except for APMV-5, which failed to infect detectably.
Except for APMV-5, each APMV induced a substantial humoral
Experimental Infection of Mice with APMV 1 to 9
PLoS ONE | www.plosone.org 8 February 2011 | Volume 6 | Issue 2 | e16776immune response. The replication of APMVs in mice produced a
spectrum of mild, short-lived disease that was restricted to the
respiratory tract. These results suggest that, like APMV-1, the
other APMV serotypes are candidates for evaluation in non-
human primates as potential vaccine vectors attenuated by host
rang restriction. In conclusion, this study is the first comparative
report on the replication and pathogenicity of prototype strains of
all nine APMV serotypes in mice. Our results lay the foundation
for a good laboratory animal model for testing the replication and
pathogenicity of APMV strains.
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